Effects of the LHRH antagonist Cetrorelix on affective and cognitive functions in rats

Regulatory Peptides

Volumn 159, Issue 1-3, 2010, Pages 142-147

  Telegdy, G ^a   Adamik, A ^a   Tanaka, M ^a   Schally, A V ^b,c  

^a UNIVERSITY OF SZEGED   (Hungary)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressive; Anxiolytic; Cetrorelix; Memory correction

Indexed keywords

AMYLOID BETA PROTEIN[25-35]; CETRORELIX; GONADORELIN ANTAGONIST; GONADOTROPIN; SEX HORMONE;

AFFECT; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; AVOIDANCE BEHAVIOR; BRAIN FUNCTION; COGNITION; CONTROLLED STUDY; CORE TEMPERATURE; DEPRESSION; DRUG DOSE COMPARISON; FORCED SWIMMING TEST; GONADOTROPIN RELEASE; HORMONE RELEASE; INHIBITION KINETICS; MALE; MAZE TEST; NONHUMAN; OPEN FIELD BEHAVIOR; PASSIVE AVOIDANCE; PRIORITY JOURNAL; RAT; SPECIES DIFFERENCE; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; MALE; MAZE LEARNING; MICE; RATS; RATS, WISTAR;

MUS; RATTUS;

EID: 71349086799     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2009.08.005     Document Type: Article

References (68)

1. Schally A.V., Kastin A.J., and Arimura A. Hypothalamic FSH and LH-regulating hormone: structure, physiology and clinical studies. Fertil Steril 22 (1971) 703-721
2. Bajusz S., Csernus V.J., Janáky T., Bokser L., Fekete M., and Schally A.V. New antagonist of LHRH. Inhibition and potentiation of LHRH by closely related analogues. Int J Pept Protein Res 32 (1988) 425-435
3. Schally A.V. LHRH analogues: their impact on reproductive medicine. Gynecol Endocrinol 13 (1999) 401-409
4. Engel J.B., and Schally A.V. Drug insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. Nat Clin Pract Endocrinol Metab 3 (2007) 157-167
5. Bokser L., Bajusz S., Groot K., and Schally A.V. Prolonged inhibition of luteinizing hormone and testosterone levels in male rats with luteinizing hormone-releasing hormone antagonist SB-75. Proc Natl Acad Sci U S A 87 (1990) 7100-7104
6. Szende B., Srkalovic G., Groot K., Lapis K., and Schally A.V. Growth inhibition of mouse MXT mammary tumor by the luteinizing hormone-releasing hormone antagonist SB-75. J Nat Cancer Inst 82 (1990) 523-617
7. Behre H.M., Klein B., Steinmeyer E., McGregor G.P., Voigt K., and Nieschlag E. Effective suppression of luteinizing hormone and testosterone by single doses of the new gonadotropin-releasing hormone antagonist Cetrorelix (SB-75) in normal men. J Clin Endocrinol Metab 75 (1992) 393-398
8. Weinbauer G.F., and Nieschlag E. Evaluation of antigonadotropic activity of different GnRH antagonists in the non-human primate. Andrologia 25 (1993) 141-147
9. Reissmann T., Schally A.V., Bouchard P., Riethmüller H., and Engel J. The LHRH antagonist Cetrorelix: a review. Hum Reprod Updat 6 (2000) 322-331
10. Telegdy G., and Rózsahegyi G. Effects of gonadotropins on extinction of an avoidance conditioned reflex and exploratory behavior in the rat. Acta Physiol Acad Sci Hung 4o (1971) 209-214
11. Telegdy G., Rózsahegyi G., and Lissák K. Further data on the effects of human chorionic gonadotropin on avoidance and exploratory behavior in the rat. Acta Physiol Acad Sci Hung 40 (1971) 215-220
12. Szontagh L., Kovacs G.L., and Telegdy G. Effect of human chorionic gonadotropin on brain monoamine content in the rats. Acta Physiol Acad Sci Hung 52 (1978) 152
13. Barrera C.M., Banks W.A., Fasold M.B., and Kastin A.J. The bidirectional transport of LHRH across the blood-brain barrier. Am J Physiol 261 (1991) E312-E318
14. Banks W.A., Kastin A.J., Olson G.A., and Olson R.D. Permeability of the blood-brain barrier and blood-testis barrier to LH, FSH, and albumin in younger and older mice. Neuroendocrinol Lett 15 (1993) 177-182
15. Lukacs H., Hiatt E.S., Lei Z.M., and Rao C.V. Peripheral and intracerebroventricular administration of human chorionic gonadotropin alters several hippocampus-associated behaviors in cyclic female rats. Horm Behav 29 (1995) 42-58
16. Masson G.M., Anthony F., and Chau E. Serum chorionic gonadotropin (hCG) schwangerschaftprotein 1 (SP1) progesterone and oestradiol levels in patients with nausea and vomiting in early pregnancy. Br J Obstet Gyneacol 92 (1985) 211-215
17. Brett M., and Baxendale S. Motherhood and memory: a review. Psychoneuroendocrinology 26 (2001) 339-362
18. Chakravarti S., Collins W.P., Forecast J.D., Newton J.R., Oram D.H., and Stud J.W. Hormonal profiles after menopause. BMJ 2 (1976) 784-787
19. Molnar G., and Kassai-Bazsa Z. Gonadotropin, ACTH, prolactin, sexual steroid and cortisol levels in postmenopausal women's cerebrospinal fluid (CSF). Arch Gerontol Geriatr 24 (1997) 269-280
20. Wittchen H.U., and Jacobi F. Size and burden of mental disorders in Europe - a critical review and appraisal of 27 studies. Eur Neuropsychopharmacol 15 (2005) 357-376
21. Noble R.E. Depression in women. Metabolism 54 (2005) 49-52
22. Garde K. Depression-gender differences. Ugeskr Laeger 169 (2007) 2422-2425
23. Mirowsky J. Age and the gender gap in depression. J Health Soc Behav 37 (1996) 362-380
24. Kramer M.S., Cutler N., Fieghner J., Shrivastava R., Carman J., Sramek J.J., Reines S.A., Liu G., Snavely D., Wyatt-Knowles E., Hale J.J., Mills S.G., MacCroee M., Swain C.J., Harrison T., Hill R.G., Hefti F., Scolnick E.M., Cascieri M.A., Chicchi G.G., Sadowski S., Williams A.R., Hewson L., Smith D., Carlson E.J., Hargreaves R.J., and Rupniak N.M. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 81 (1998) 1640-1645
25. Holsboer F. The rational for corticotrophin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J Psychiat Res 33 (1999) 181-214
26. Landgraf R. Neuropeptides and anxiety-related behavior. Endocrinology 148 (2001) 517-533
27. Bowen R.L., Smith M.A., Harris P.L., Kubat Z., Martins R.N., Castellani R.J., Perry G., and Atwood C.S. Elevated luteinizing hormone expression with neurons vulnerable to Alzheimer's disease pathology. J Neurosci Res 70 (2002) 514-518
28. Meethal S.V., Smith M.A., Bowen R.L., and Atwood C.S. The gonadotropin connection in Alzheimer's disease. Endocrine 26 (2005) 317-326
29. Casadesus G., Webber K.M., Atwood C.S., Papolla M.A., Perry G., Bowen R.L., and Smith M.A. Lueinizing hormone modulates cognition and amyloid-beta deposition in Alzheimer APP transgenic mice. Biochim Biophys Acta 1762 (2006) 447-452
30. Barron A., Verdile G., and Martins R.N. The role of gonadotropins in Alzheimer's disease. Endocrine 29 (2006) 257-269
31. Telegdy G., Tanaka M., and Schally A.V. Effects of the LHRH antagonist Cetrorelix on the brain function in mice. Neuropeptides 43 (2009) 229-234
32. Pellegrino I.J., Pellegrino A.S., and Cushman A.J. Stereotaxic atlas of the rat brain (1979), Plenum Press, New York 8-57
33. Ader R., Weijnen J.A.W.M., and Moleman P. Retention of a passive avoidance response as a function of the intensity and duration of electric shock. Psychosom Sci 26 (1972) 126-128
34. Pellow S., Chopin P., File S., and Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14 (1985) 149-167
35. Detke M.J., Rickels M., and Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology (Berl) 121 (1995) 66-72
36. Khisti R.T., Chopde C.T., and Jain S.P. Antidepressant-like effect of the neurosteroid 3alpha-hydroxy-5alpha-pregnan-20-one in mice forced swim test. Pharmacol Biochem Behav 67 (2000) 137-143
37. Chen S., Wright J.W., and Barnes C.D. The neurochemical and behavioral effects of beta-amyloid peptide (25-35). Brain Res 720 (1996) 54-60
38. Yamaguchi Y., and Kawashima S. Effects of amyloid-beta-(25-35) on passive avoidance, radial-arm maze learning and choline acetyltransferase activity in the rat. Eur J Pharmacol 412 (2001) 265-272
39. Stepanichev M.Y., Moiseeva Y.V., Lazareva N.A., Onufriev M.V., and Gulyaeva N.Y. Single intracerebroventricular administration of amyloid-beta (25-35) peptide induces impairment in short-term rather than long term memory in rats. Brain Res Bull 61 (2003) 197-205
40. Roesler R., Luft T., Oliveira S.H.S., Farias C.B., Almeida V.R., Quevedo J., Dal Pizzol F., Schröder N., Izquierdo I., and Schwartsmann G. Molecular mechanisms mediating gastrin-releasing peptide receptor modulation of memory consolidation in the hippocampus. Neuropharmacology 51 (2006) 350-357
41. Rosenberg R.N. The molecular and genetic basis of AD: the end of the beginning: the 2000. Wartenberg Lecture. Neurology 54 (2000) 2045-2054
42. Sambamurti K., Greigh N.H., and Lahiri D.K. Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease. Neuromolecular Med 1 (2002) 1-31
43. Banks W.A., and Morley J.E. Memories are made of this: recent advances in understanding cognitive impairments and dementia. J Gerontol 58 (2003) AM314-21
44. Shumaker S.A., Legault C., Rapp S.R., Thai L., Wallace R.B., Ockene J.K., Hendrix S.L., Jones B.N., Assaf A.R., Jackson R.D., Kotchen J.M., Wassertheil-Smoller S., and Wactawski-Wende J. Estrogen plus progestin and incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 289 (2003) 2651-2662
45. Heikkinen T., Kolesnykas G., Rissanen A., Tapiola T., Ivonene S., Wang J., Chaudhuri J., Tanila H., Miettinen R., and Puolivali J. Estrogen treatment improves spatial learning in APP+PSI mice but does not affect beta amyloid accumulation and plaque formation. Exp Neurol 187 (2004) 105-117
46. Casadesus G., Atwood C.S., Zhu X., Hartzler A.W., Webber K.M., Perry G., Bowen R.L., and Smith M.A. Evidence for the role of gonadotropin hormones in the development of Alzheimer disease. Cell Mol Life Sci 62 (2005) 293-298
47. Weber K.M., Casadesus G., Bowen R.L., Perry G., and Smith M.A. Evidence for the role of luteinizing hormone in Alzheimer disease. Endocr Metab Immune Disord Drug Targets 7 (2007) 300-303
48. Bekker M.H.J., and van Mens-Verlust J. Axiety disorders: sex differences in prevalence, degree, and background, but gender-neutral treatment. Gend Med 4 Suppl.B (2007) 178-193
49. Breslau N., Chilcoat H., and Schultz L.R. Anxiety disorder and the emergence of sex differences in major depression. J Gend Specif Med 1 (1998) 33-39
50. Parker G., and Hadzi-Pavlovic D. Is any female preponderance in depression secondary to a primary female preponderance in anxiety disorders?. Acta Psychiatr Scand 103 (2001) 252-256
51. Breaslau N., Schultz L., and Peterson E. Sex differences in depression: role of preexisting anxiety. Psychiatry Res 8 (1995) 1-12
52. Dal Forno G., Palermo M.T., Donohue J.E., Karagiozis H., Zonderman A.B., and Kawas C.H. Depressive symptoms, sex and risk for Alzheimer's disease. Ann Neurol 57 (2005) 381-387
53. Shors T.J., and Leuner B. Estrogen-mediated effects on depression and memory formation in females. J Affect Disord 74 (2003) 85-96
54. Seeman M.V. Psychopathology in women and man: focus on female hormones. Am J Psychiatry 154 (1997) 1641-1647
55. Bromberger J.T. A psychosocial understanding of depression in women: for the primary care physician. J Am Med Womens Assoc 59 (2004) 198-206
56. Norbury R., Cutter W.J., Compton J., Robertson D.M., Craig M., Whithead M., and Murphy D.G. The neuroprotective effects of estrogen on the aging brain. Exp Gerontol 38 (2003) 109-117
57. Halbreich U., and Kahn L.S. Role of estrogen in the aetiology and treatment of mood disorders. CNS Drugs 15 (2001) 797-817
58. Compton J., van Amelsvoort T., and Murphy D. Mood, cognition and Alzheimer's disease. Best Pract Res Clin Obstet Gynecol 16 (2002) 357-370
59. Kádár T., Telegdy G., and Schally A.V. Partial reversal of behavioral action of the agonist D-TRP-6-LH-RH by naloxone in mice. Life Sci 46 (1990) 463-470
60. Kádár T., Telegdy G., and Schally A.V. Neuropharmacological actions of the superactive agonist analog D-TRP-6-LH-RH after peripheral injection into mice. Neuropeptides 17 (1990) 81-86
61. Schally A.V., Comaru-Schally A.M., Nagy A., Kovacs M., Szepeshazi K., Plonowski A., Varga J.L., and Halmos G. Hypothalamic hormones and cancer. Front Neuroendocrinol 22 (2001) 248-291
62. Bowen R.L., Verdile G., Liu T., Parlow A.F., Perry G., Smith M.A., Martins R.N., and Atwood G. Luteinizing hormone, a reproductive regulator that modulates the processing of amyloid-β deposition. J Biol Chem 279 (2004) 20539-20545
63. Wilson A.C., Meethal S.V., Bowen R.L., and Atwood C.S. Leuprolide acetate: a drug of diverse clinical applications. Expert Opin Investig 16 (2007) 1851-1863
64. Umathe S.N., Bhutada P.S., Jain N.S., Shukla N.R., Mundhada Y.R., and Dixit P.V. Gonadotropin-releasing hormone agonist blocks anxiogenic-like and depressant-like effect of corticotrophin-releasing hormone in mice. Neuropeptides 42 (2008) 399-410
65. Uday G., Pravinkumar B., Manish W., and Sudhir U. LHRH antagonist attenuates the effect of fluoxetine on marble-burying behavior in mice. Eur J Pharmacol 563 (2007) 155-159
66. Berry A., Tomidokoro Y., Ghiso J., and Thorton J. Human chorionic gonadotropin (a luteinizing hormone homologue) decreases spatial memory and increases brain amyloid-beta levels in female rats. Horm Behav 54 (2008) 143-152
67. Toth P., Lukacs H., Hiatt E.S., Reid K.H., Iyer V., and Rao C.V. Administration of human chorionic gonadotropin affect sleep-wake phases and other associated behaviors in cycling female rats. Brain Res 654 (1994) 181-190
68. Lukacs H. Rat as model for studying behavior effects of hCG. Semin Reprod Med 19 (2001) 111-119